CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Budesonide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01955980
NCT01955980Phase 2Completed

A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes® Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis

Pari Pharma GmbH·interventional·Posted Oct 8, 2013·Updated Apr 12, 2022

In Brief

A Phase 2 clinical trial evaluating Budesonide for Rhinosinusitis. Completed, enrolled 19 participants across 3 sites.

Detailed Summary

The study should create data for the selection of a clinically relevant endpoint to assess the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic Rhinosinusitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinosinusitis
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 8, 2013
Enrollment StartOct 27, 2015
Primary CompletionSep 27, 2018
Study CompletionJul 29, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.7 years ago

Interventions

Budesonidedrug

Inhalation

Budesonidedrug

Nasal Spray